Tvardi Therapeutics, Inc. (TVRD) Market Cap
Tvardi Therapeutics, Inc. has a market capitalization of $30.2M.
Financials based on reported quarter end 2025-12-31
Price: $3.22
▲ 0.06 (1.90%)
Market Cap: 30.21M
NASDAQ · time unavailable
CEO: Imran Alibhai
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2025-04-16
Tvardi Therapeutics, Inc. (TVRD) - Company Information
Market Cap: 30.21M · Sector: Healthcare
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Analyst Sentiment
Based on 4 ratings
Analyst 1Y Forecast: $30.20
Average target (based on 1 sources)
Consensus Price Target
Low
$3
Median
$3
High
$3
Average
$3
Downside: -6.8%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
Management is upbeat on NP: COURAGE I Part A enrollment is complete ahead of schedule and topline is targeted for Q3, with a clear intention to pick (ideally) a single BID dose for the pivotal Part B based on Part A plus KOMFORT and that 2 mg BID has shown early statistically significant itch separation. However, the Q&A pressure surfaced key execution uncertainties. Analysts probed whether “success” on the 4-point itch NRS at week 8 is realistic and how to handle potentially higher placebo; management admitted the study isn’t powered for statistical significance and expects placebo may be slightly higher due to 3:1 randomization, more sites, and increased awareness. In parallel, the commercial picture is de-risked but deteriorating: unfavorable reimbursement changes after TDAPA ends March 31, 2024 are expected to drive dialysis protocol restrictions, with no meaningful KORSUVA revenue going forward. The tone in prepared remarks emphasizes cash runway into 2026, but Q&A highlights clinical interpretability and endpoint validity as near-term hurdles.
Growth Catalysts
- KORSUVA injection demand growth: vial shipments to clinics increased 22% QoQ to 110,000 vials in Q4 2023
- Oral difelikefalin (oral DSK) COURAGE I Part A enrollment completed ahead of schedule; topline efficacy/safety targeted for Q3 2024
- Phase 2 KOMFORT proof-of-concept: 2 mg BID produced statistically significant separation from placebo on worst itch NRS by day 1 and sustained efficacy through 8-week double-blind period (published NEJM)
Business Development
- HealthCare Royalty (HCR) financing transaction completed in Q4 2023; brought forward ex-US and Japan royalties (non-dilutive)
- Collaborative revenue from CSL Vifor profit share on KORSUVA sales (collaborative revenue includes $2.3M in Q4 2023 tied to CSL Vifor sales)
- CSL and Maruishi royalty streams referenced under the HCR agreement (royalties received recorded as non-cash other revenue)
Financial Highlights
- KORSUVA net sales: $5M in Q4 2023; reported revenue $3.0M vs $3.3M in Q4 2022
- Q4 2023 revenue composition: $2.3M collaborative revenue (CSL Vifor profit share) + $0.7M other revenue (HCR royalties/milestones)
- Wholesale shipments: 110,000 vials in Q4 (22% increase QoQ); majority reallocated within Fresenius clinic network (no incremental revenue)
- Cost of goods sold: $0.6M in Q4 2023 vs $2.1M in Q4 2022; includes inventory adjustment charges rather than incremental vials shipped to CSL
- R&D expense: $28.4M in Q4 2023 vs $26.0M in Q4 2022; includes $1.7M manufacturing commitment expense no longer needed due to reduced US demand expectations for KORSUVA
- Cash and equivalents + marketable securities: $100.8M at 12/31/23 vs $156.7M at 12/31/22; decrease driven by $92.1M operating cash used offset by $36.5M net HCR proceeds
- Cash runway: unrestricted cash/cash equivalents/available-for-sale and marketable securities expected to fund operating plan into 2026
Capital Funding
- HCR transaction in Q4 2023: $36.5M net proceeds received (cash impact referenced in Q4 results)
- Cash runway extended into 2026; prioritization funded via succession of clinical milestones through early/mid-2026
Strategy & Ops
- January 2024 strategic prioritization: focus resources on oral difelikefalin for notalgia paresthetica (NP); extend cash runway into 2026 to reach value inflection milestones
- COURAGE I Part A: completed enrollment; trial design noted as 8-week, double-blind, placebo-controlled with three active arms and 3:1 randomization; Q3 targeted topline
- Dosing schedule: twice-daily (BID) maintained due to renal excretion and PK; once-daily was not pursued
- Manufacturing commitments: $1.7M R&D expense in Q4 related to commitments no longer needed due to reduced KORSUVA US demand expectations
Market Outlook
- KORSUVA: management does not expect meaningful revenue contributions going forward due to unfavorable reimbursement changes after TDAPA period end (March 31, 2024)
- NP (COURAGE I): topline efficacy and safety results expected in Q3 2024
Risks & Headwinds
- KORSUVA reimbursement risk: after TDAPA period ends March 31, 2024, management expects dialysis organizations to modify protocols and significantly restrict access to KORSUVA
- Revenue optics risk: Q4 wholesaler shipments (110,000 vials) largely represented inventory reallocated within Fresenius network, not incremental Cara revenue
- Clinical placebo risk: management expects placebo response may be slightly higher in COURAGE I Part A vs KOMFORT due to 3:1 randomization (patients may feel on active), more sites, and greater awareness from NEJM publication/late breakers
- Quality-of-life (QoL) endpoint uncertainty: management stated NP QoL tools are not necessarily relevant to NP; still navigating appropriate QoL endpoints despite seeing QoL measures in KOMFORT
Sentiment: CAUTIOUS
Note: This summary was synthesized by AI from the TVRD Q4 2023 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.